- Home
- TRU vs RPRX Comparison
TRU vs RPRX Comparison
Compare TRU & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRU
- RPRX
- Stock Information
- Founded
- TRU 1968
- RPRX 1996
- Country
- TRU United States
- RPRX United States
- Employees
- TRU N/A
- RPRX N/A
- Industry
- TRU Finance: Consumer Services
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- TRU Finance
- RPRX Health Care
- Exchange
- TRU Nasdaq
- RPRX Nasdaq
- Market Cap
- TRU 16.6B
- RPRX 16.2B
- IPO Year
- TRU 2015
- RPRX 2020
- Fundamental
- Price
- TRU $80.91
- RPRX $38.74
- Analyst Decision
- TRU Buy
- RPRX Strong Buy
- Analyst Count
- TRU 12
- RPRX 3
- Target Price
- TRU $104.45
- RPRX $46.00
- AVG Volume (30 Days)
- TRU 2.9M
- RPRX 3.5M
- Earning Date
- TRU 10-23-2025
- RPRX 11-05-2025
- Dividend Yield
- TRU 0.57%
- RPRX 2.28%
- EPS Growth
- TRU 87.22
- RPRX N/A
- EPS
- TRU 2.14
- RPRX 1.75
- Revenue
- TRU $4,441,800,000.00
- RPRX $2,349,844,000.00
- Revenue This Year
- TRU $9.57
- RPRX $36.16
- Revenue Next Year
- TRU $7.31
- RPRX $2.04
- P/E Ratio
- TRU $37.60
- RPRX $22.00
- Revenue Growth
- TRU 8.30
- RPRX 3.70
- 52 Week Low
- TRU $66.38
- RPRX $24.05
- 52 Week High
- TRU $108.12
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- TRU 47.53
- RPRX 57.20
- Support Level
- TRU $78.34
- RPRX $38.39
- Resistance Level
- TRU $80.80
- RPRX $41.24
- Average True Range (ATR)
- TRU 2.21
- RPRX 1.16
- MACD
- TRU 0.08
- RPRX 0.21
- Stochastic Oscillator
- TRU 28.32
- RPRX 50.33
About TRU TransUnion
TransUnion is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries. About 20%-25% of its revenue comes from international markets.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.